急性期の興奮・攻撃性治療の世界市場レポート 2025年

急性期の興奮・攻撃性治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には77億7,000万米ドルに成長し、CAGRは6.4%となります。予測期間の成長は、高齢化人口の増加、ヘルスケアインフラの整備、製薬業界投資の増加、在宅医療の増加、可処分所得の増加などに起因すると考えられます。予測期間の主な動向には、非薬理学的介入、精密医療、AIと予測分析、地域ベースのサポート、業界連携などがあります。

予想される急性期の興奮・攻撃性治療市場の拡大は、いくつかの重要な要因と密接に結びついています。まず、認知症罹患率の増加が原動力になると予想されます。認知症は、認知機能の障害や日常業務の遂行不能を特徴とする病態であり、しばしば興奮や落ち着きのなさといった症状を引き起こします。これらの症状を管理し、患者のQOLを向上させ、興奮の根本原因に対処するには、効果的な治療が不可欠です。例えば、2023年2月のオーストラリア保健福祉研究所のデータによると、オーストラリアでは認知症患者が大幅に増加し、2058年には84万9,300人に達すると予想されており、この分野の治療の必要性が浮き彫りになっています。

精神疾患の有病率の増加は、今後数年間の急性期の興奮・攻撃性治療市場の拡大を牽引すると予想されます。精神疾患とは、個人の認知、感情、心理、行動機能に影響を及ぼす病状を指します。このような状態では、しばしば急性期の興奮や攻撃性の治療が必要となり、破壊的で潜在的に有害な行動を管理し、罹患者と周囲の人々の安全を確保すると同時に、根本的な心理的苦痛に対処し、全体的な幸福を促進します。例えば、米国を拠点とする非部門公的機関であるNHS Business Services Authorityによると、2023年12月、抗うつ薬の処方は1.5％増加し、2,200万件、患者数は680万人に達しました。また、催眠薬、抗不安薬、精神病治療薬の処方も増加し、認知症治療薬が3.1％増の110万件と最も増加しました。その結果、精神疾患の負担の増大が、急性期の興奮・攻撃性治療の需要を押し上げています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性期の興奮・攻撃性治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性期の興奮・攻撃性治療市場：成長率分析
• 世界の急性期の興奮・攻撃性治療市場の実績：規模と成長, 2019-2024
• 世界の急性期の興奮・攻撃性治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性期の興奮・攻撃性治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性期の興奮・攻撃性治療市場治療アプローチ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 行動アプローチ
• 環境介入
• 薬理学的アプローチ
• 世界の急性期の興奮・攻撃性治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗精神病薬
• ベンゾジアゼピン
• その他の薬物クラス
• 世界の急性期の興奮・攻撃性治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 筋肉内
• その他の投与経路
• 世界の急性期の興奮・攻撃性治療市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 統合失調症
• 痴呆
• 双極性障害
• うつ
• 薬物誘発性の興奮と攻撃性
• アルコール離脱
• その他の適応症
• 世界の急性期の興奮・攻撃性治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院および外来手術センター
• 精神科医療施設
• その他のエンドユーザー
• 世界の急性期の興奮・攻撃性治療市場行動アプローチのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 認知行動療法（CBT）
• 弁証法的行動療法（DBT）
• リラクゼーションテクニックと緊張緩和戦略
• 怒り管理プログラム
• 世界の急性期の興奮・攻撃性治療市場環境介入の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 安全で落ち着いた環境を作る（例：静かな部屋）
• 感覚調節技術
• 制限的措置（例：身体拘束）
• 攻撃性管理のための環境調整
• 世界の急性期の興奮・攻撃性治療市場薬理学的アプローチの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗精神病薬
• ベンゾジアゼピン
• 抗うつ薬
• 気分安定剤
• 鎮静剤および抗不安薬

第7章 地域別・国別分析

• 世界の急性期の興奮・攻撃性治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性期の興奮・攻撃性治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性期の興奮・攻撃性治療市場：競合情勢
• 急性期の興奮・攻撃性治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Pvt Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co Ltd.
• Mylan NV
• Biogen Inc.
• Bausch Health Companies Inc.
• UCB SA
• Servier Laboratories
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca PLC
• Ono Pharmaceutical Co Ltd.
• Apotex Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性期の興奮・攻撃性治療市場2029：新たな機会を提供する国
• 急性期の興奮・攻撃性治療市場2029：新たな機会を提供するセグメント
• 急性期の興奮・攻撃性治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Treatment for acute agitation and aggression addresses the sudden onset of restlessness, irritability, and hostility in patients, aiming to manage and alleviate these symptoms. Such behaviors can be manifestations of underlying conditions like psychiatric disorders, neurological issues, or substance use or withdrawal effects.

The primary methods for managing acute agitation and aggression encompass behavioral, environmental, and pharmacological approaches. The behavioral approach involves the scientific study of observable behavior and its environmental triggers, emphasizing psychological perspectives. Pharmacologic approaches often employ diverse drugs, such as anti-psychotics, benzodiazepines, and others, administered through various routes like oral or intramuscular. These treatments target conditions such as schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation, alcohol withdrawal, and more. They are utilized across various settings, including hospitals, ambulatory surgical centers, psychiatric care facilities, and other healthcare environments.

The acute agitation and aggression treatment market research report is one of a series of new reports from The Business Research Company that provides acute agitation and aggression treatment market statistics, including acute agitation and aggression treatment industry global market size, regional shares, competitors with acute agitation and aggression treatment market share, detailed acute agitation and aggression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acute agitation and aggression treatment industry. This acute agitation and aggression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute agitation and aggression treatment market size has grown strongly in recent years. It will grow from $5.72 billion in 2024 to $6.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to advances in pharmacology, rise in clinical research, regulatory approvals, rise in prevalence of acute agitation and aggression cases, increased awareness regarding mental health.

The acute agitation and aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing aging population, growing healthcare infrastructure, rising pharmaceutical industry investment, rise in home-base care, rise in disposable income. Major trends in the forecast period include non-pharmacological interventions, precision medicine, ai and predictive analytics, community-based support, industry collaboration.

The anticipated expansion of the acute agitation and aggression treatment market is closely tied to several significant factors. Firstly, the increasing incidence of dementia is expected to be a driving force. Dementia, a condition marked by cognitive impairments and an inability to perform daily tasks, often leads to symptoms like agitation and restlessness. Effective treatment is crucial in managing these symptoms, improving the patient's quality of life, and addressing the root causes of agitation. For instance, according to data from the Australian Institute of Health and Welfare in February 2023, Australia is expected to see a substantial rise in dementia cases, reaching 849,300 by 2058, highlighting the need for treatments in this area.

The growing prevalence of mental illness is expected to drive the expansion of the acute agitation and aggression treatment market in the coming years. Mental illness refers to medical conditions that affect an individual's cognitive, emotional, psychological, or behavioral functions. These conditions often necessitate treatments for acute agitation and aggression to manage disruptive and potentially harmful behaviors, ensuring both the safety of the affected individual and those around them, while also addressing the underlying psychological distress and promoting overall well-being. For example, in December 2023, according to the NHS Business Services Authority, a US-based non-departmental public body, antidepressant prescriptions increased by 1.5%, reaching 22 million, with 6.8 million patients. There were also increases in prescriptions for hypnotics, anxiolytics, and psychosis drugs, with dementia medications seeing the largest rise, up 3.1% to 1.1 million items. As a result, the growing burden of mental illness is driving the demand for acute agitation and aggression treatments.

Major companies within the acute agitation and aggression treatment market are actively engaged in innovative product development and approvals, exemplified by IGALMI (dexmedetomidine). IGALMI, a sublingual film, has received FDA approval and offers a new treatment avenue for individuals dealing with agitation associated with schizophrenia or bipolar disorders. Developed by BioXcel Therapeutics Inc. in April 2022, this fast-acting and short-duration medication represents an advancement in addressing severe or life-threatening conditions. These developments contribute to the evolving landscape of treatments within the market.

Major companies operating in the acute agitation and aggression treatment market are focusing on developing innovative products, such as a generic version of Zyprexa, to address the needs of patients. Generic Zyprexa is a version of the brand-name drug Zyprexa, which contains the active ingredient olanzapine and is used to treat psychotic conditions. For instance, in September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, launched a generic version of Zyprexa. This atypical antipsychotic drug is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania.

In April 2023, SK Capital Partners LP, a private investment firm based in the United States, completed the acquisition of Apotex Inc., a renowned Canada-based generic pharmaceutical company. The acquisition, for an undisclosed sum, represents a strategic move enabling SK Capital to broaden its presence within the generic pharmaceutical sector. Apotex's specialization in producing medications for treating acute agitation and aggression aligns with SK Capital's extended investment pursuits in the healthcare industry.

Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

North America was the largest region in the acute agitation and aggression treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute agitation and aggression treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute agitation and aggression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The acute agitation and aggression treatment market includes revenues earned by entities by providing treatment with de-escalation techniques, psychosocial support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute agitation and aggression treatment market also consists of sales of lorazepam, chlorpromazine, and quetiapine API, droperidol, olanzapine, and ziprasidone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Agitation And Aggression Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute agitation and aggression treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute agitation and aggression treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute agitation and aggression treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Approach: Behavioral Approaches; Environmental Interventions; Pharmacologic Approaches
• 2) By Drug Class: Anti-Psychotics; Benzodiazepines; Other Drug Classes
• 3) By Route of Administration: Oral; Intramuscular; Other Routes of Administrations
• 4) By Indication: Schizophrenia; Dementia; Bipolar Disorder; Depression; Drug-Induced Agitation And Aggression; Alcohol Withdrawal; Other Indications
• 5) By End User: Hospitals And Ambulatory Surgical Centers; Psychiatric Care Facilities; Other End Users
• Subsegments:
• 1) By Box Style: Standard Box Action Cameras; Modular Box Action Cameras
• 2) By Cube Style: Compact Cube Action Cameras; Cube Cameras with Integrated Mounts
• 3) By Bullet Style: Long, Cylindrical Action Cameras; Mountable Bullet Cameras
• 4) By Periscope & 360°: 360-Degree Cameras; Periscope Cameras
• 5) By Other Types: Wearable Action Cameras; Drone Action Cameras; Specialty Action Cameras
• Companies Mentioned: Pfizer Inc.;Johnson and Johnson Pvt Ltd.;F Hoffmann-La Roche Ltd.;AbbVie Inc.;Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Agitation And Aggression Treatment Market Characteristics

3. Acute Agitation And Aggression Treatment Market Trends And Strategies

4. Acute Agitation And Aggression Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Agitation And Aggression Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Agitation And Aggression Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Agitation And Aggression Treatment Market Growth Rate Analysis
• 5.4. Global Acute Agitation And Aggression Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Agitation And Aggression Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Agitation And Aggression Treatment Total Addressable Market (TAM)

6. Acute Agitation And Aggression Treatment Market Segmentation

• 6.1. Global Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Behavioral Approaches
• Environmental Interventions
• Pharmacologic Approaches
• 6.2. Global Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Psychotics
• Benzodiazepines
• Other Drug Classes
• 6.3. Global Acute Agitation And Aggression Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intramuscular
• Other Routes of Administrations
• 6.4. Global Acute Agitation And Aggression Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Drug-Induced Agitation And Aggression
• Alcohol Withdrawal
• Other Indications
• 6.5. Global Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Ambulatory Surgical Centers
• Psychiatric Care Facilities
• Other End Users
• 6.6. Global Acute Agitation And Aggression Treatment Market, Sub-Segmentation Of Behavioral Approaches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Behavioral Therapy (CBT)
• Dialectical Behavior Therapy (DBT)
• Relaxation Techniques and De-escalation Strategies
• Anger Management Programs
• 6.7. Global Acute Agitation And Aggression Treatment Market, Sub-Segmentation Of Environmental Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Creating Safe and Calm Environments (e.g., quiet rooms)
• Sensory Modulation Techniques
• Restrictive Measures (e.g., physical restraints)
• Environmental Adjustments for Aggression Management
• 6.8. Global Acute Agitation And Aggression Treatment Market, Sub-Segmentation Of Pharmacologic Approaches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antipsychotic Medications
• Benzodiazepines
• Antidepressants
• Mood Stabilizers
• Sedative and Anxiolytic Medications

7. Acute Agitation And Aggression Treatment Market Regional And Country Analysis

• 7.1. Global Acute Agitation And Aggression Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Agitation And Aggression Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Agitation And Aggression Treatment Market

• 8.1. Asia-Pacific Acute Agitation And Aggression Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Agitation And Aggression Treatment Market

• 9.1. China Acute Agitation And Aggression Treatment Market Overview
• 9.2. China Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Agitation And Aggression Treatment Market

• 10.1. India Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Agitation And Aggression Treatment Market

• 11.1. Japan Acute Agitation And Aggression Treatment Market Overview
• 11.2. Japan Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Agitation And Aggression Treatment Market

• 12.1. Australia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Agitation And Aggression Treatment Market

• 13.1. Indonesia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Agitation And Aggression Treatment Market

• 14.1. South Korea Acute Agitation And Aggression Treatment Market Overview
• 14.2. South Korea Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Agitation And Aggression Treatment Market

• 15.1. Western Europe Acute Agitation And Aggression Treatment Market Overview
• 15.2. Western Europe Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Agitation And Aggression Treatment Market

• 16.1. UK Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Agitation And Aggression Treatment Market

• 17.1. Germany Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Agitation And Aggression Treatment Market

• 18.1. France Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Agitation And Aggression Treatment Market

• 19.1. Italy Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Agitation And Aggression Treatment Market

• 20.1. Spain Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Agitation And Aggression Treatment Market

• 21.1. Eastern Europe Acute Agitation And Aggression Treatment Market Overview
• 21.2. Eastern Europe Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Agitation And Aggression Treatment Market

• 22.1. Russia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Agitation And Aggression Treatment Market

• 23.1. North America Acute Agitation And Aggression Treatment Market Overview
• 23.2. North America Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Agitation And Aggression Treatment Market

• 24.1. USA Acute Agitation And Aggression Treatment Market Overview
• 24.2. USA Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Agitation And Aggression Treatment Market

• 25.1. Canada Acute Agitation And Aggression Treatment Market Overview
• 25.2. Canada Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Agitation And Aggression Treatment Market

• 26.1. South America Acute Agitation And Aggression Treatment Market Overview
• 26.2. South America Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Agitation And Aggression Treatment Market

• 27.1. Brazil Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Agitation And Aggression Treatment Market

• 28.1. Middle East Acute Agitation And Aggression Treatment Market Overview
• 28.2. Middle East Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Agitation And Aggression Treatment Market

• 29.1. Africa Acute Agitation And Aggression Treatment Market Overview
• 29.2. Africa Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Agitation And Aggression Treatment Market, Segmentation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Agitation And Aggression Treatment Market Competitive Landscape And Company Profiles

• 30.1. Acute Agitation And Aggression Treatment Market Competitive Landscape
• 30.2. Acute Agitation And Aggression Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Pvt Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Acute Agitation And Aggression Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. GlaxoSmithKline plc.
• 31.4. Eli Lilly and Company
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Otsuka Pharmaceutical Co Ltd.
• 31.7. Mylan NV
• 31.8. Biogen Inc.
• 31.9. Bausch Health Companies Inc.
• 31.10. UCB SA
• 31.11. Servier Laboratories
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. AstraZeneca PLC
• 31.14. Ono Pharmaceutical Co Ltd.
• 31.15. Apotex Inc.

32. Global Acute Agitation And Aggression Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Agitation And Aggression Treatment Market

34. Recent Developments In The Acute Agitation And Aggression Treatment Market

35. Acute Agitation And Aggression Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Acute Agitation And Aggression Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Agitation And Aggression Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Agitation And Aggression Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer